Schenning, Katie J. https://orcid.org/0000-0002-1784-0749
Murchison, Charles F.
Mattek, Nora C.
Kaye, Jeffrey A.
Quinn, Joseph F.
Funding for this research was provided by:
National Institutes of Health (K12 HD 043488, P30AG024978, R01AG024059, P30AG008017)
U.S. Department of Veterans Affairs (Merit Review)
Alzheimer's Association (Clinician Scientist Fellowship)
Article History
Received: 20 July 2018
Accepted: 14 March 2019
First Online: 29 March 2019
Ethics approval and consent to participate
: All studies were approved by the Oregon Health & Science University’s institutional review board (IRB), and all participants provided written informed consent. Electronic IRB (eIRB) numbers are as follows: eIRB 361 Oregon Brain Aging Study (OBAS), eIRB 2353 Intelligent Systems for Assessment of Aging Changes (ISAAC), eIRB 688 Klamath Exceptional Aging, eIRB 1480 African American Dementia and Aging Project (AADAPt), eIRB 1639 Oregon Community Brain Donor Program (CBDP), eIRB 2765 Oregon Living Laboratory (OLL), eIRB 725 Layton Alzheimer’s Disease Center patient registry. Whenever possible, investigators obtained valid informed consent directly from the research participant. If the research participant lacks decision-making capacity, the investigator obtains consent from an Authorized Research Representative (ARR). If at any point the participant expresses resistance or dissent to participation or to the use of ARR consent, the participant is excluded from the research study. The participant may designate an ARR when the participant has adequate decision-making capacity to do so, or an ARR may be identified by the investigator in the same manner that a decision maker for health care treatment would be identified. An investigator still obtains assent of the participant in addition to consent from the ARR.
: Not applicable
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.